România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

takeda gmbh - germania - ciclesonidum - sol. de inhalat presurizata - 160micrograme/doza - alte med. pt. trat. bolilor obstructive ale c.r, inhalatorii glucocorticoizi

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

takeda gmbh - germania - ciclesonidum - sol. de inhalat presurizata - 80micrograme/doza - alte med. pt.trat.bolilor obstructive ale c.r, inhalatorii glucocorticoizi

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

glaxosmithkline consumer healthcare aps - danemarca - combinatii (cetirizinum+hydrocortisonum) - crema - 50mg/10mg/g - chimioterapice de uz local antivirale

Uniunea Europeană - română - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

corden pharma gmbh - germania - bicalutamidum - compr. film. - 150mg - antagonisti hormonali si substante inrudite antiandrogeni

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

corden pharma gmbh - germania - bicalutamidum - compr. film. - 50mg - antagonisti hormonali si substante inrudite antiandrogeni

Uniunea Europeană - română - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

corden pharma gmbh - germania - bicalutamidum - compr. film. - 150mg - antagonisti hormonali si substante inrudite antiandrogeni

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

corden pharma gmbh - germania - bicalutamidum - compr. film. - 50mg - antagonisti hormonali si substante inrudite antiandrogeni

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agenți antineoplazici - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.